New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2013
10:01 EDTEFX, EAT, UAL, BSRR, ESI, COLM, AMZN, F, WDC, SHPG, MPWR, FRX, CECO, AAP, MCK, CL, SNE, RMD, VLCCF, DD, CYSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Advance Auto Parts (AAP) upgraded to Outperform from Sector Perform at RBC Capital... Amazon.com (AMZN) upgraded to Strong Buy from Market Perform at Raymond James... CYS Investments (CYS) upgraded to Neutral from Underperform at BofA/Merrill... Career Education (CECO) upgraded to Outperform from Market Perform at Wells Fargo... Columbia Sportswear (COLM) upgraded to Neutral from Sell at Citigroup... DuPont (DD) upgraded to Buy from Neutral at Citigroup... Forest Labs (FRX) upgraded to Market Perform from Underperform at BMO Capital... ITT Educational (ESI) upgraded to Neutral from Sell at Compass Point... Knightsbridge Tankers (VLCCF) upgraded to Equal Weight from Underweight at Evercore... Monolithic Power (MPWR) upgraded to Outperform from Perform at Oppenheimer... Sierra Bancorp (BSRR) upgraded to Market Perform from Underperform at Raymond James... ResMed (RMD) upgraded to Buy from Neutral at UBS... Shire (SHPG) upgraded to Buy from Neutral at BofA/Merrill... United Continental (UAL) upgraded to Buy from Neutral at Buckingham... Sony (SNE) upgraded to Outperform from Neutral at Credit Suisse... Western Digital (WDC) upgraded to Hold from Sell at Craig-Hallum... Brinker (EAT) upgraded to Buy from Hold at Wunderlich... Ford (F) upgraded to Outperform from Underperform at CLSA... Colgate-Palmolive (CL) upgraded to Hold from Sell at Canaccord... Equifax (EFX) upgraded to Outperform from Neutral at RW Baird... McKesson (MCK) upgraded to Overweight from Equal Weight at Morgan Stanley.
News For AAP;AMZN;CYS;CECO;COLM;DD;FRX;ESI;VLCCF;MPWR;BSRR;RMD;SHPG;UAL;SNE;WDC;EAT;CL;F;EFX;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
May 13, 2015
07:31 EDTMCKHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:23 EDTEFXJPMorgan to hold a conference
Business Services Conference is being held in New York on May 13-14.
05:39 EDTRMDResMed announces SERVE-HF study did not meet primary endpoint
ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care. The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure. The results from SERVE-HF are preliminary and will be submitted for future publication after further analysis. A preliminary analysis of the data identified a statistically significant 2.5% absolute increased risk of cardiovascular mortality for those patients in the trial who received ASV therapy per year compared to those in the control group. In the study, the cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% per year in the control group. There were no issues associated with the performance of the ASV therapy device in the trial. ResMed is working with global regulatory authorities to proactively revise the labels and instructions for use for ResMed ASV devices to include a contraindication for people with symptomatic chronic heart failure. The company is also proactively informing healthcare providers, physicians, and patients of the cardiovascular safety signal observed in SERVE-HF.
May 12, 2015
16:25 EDTESIOn The Fly: Top stock stories for Tuesday
Stocks began the session deep in negative territory as bond yields in Europe and the U.S. were moving higher. The market saw its lows shortly after the open and soon began to recapture some of its losses. By noon, the losses were cut in half and the Dow made it all the way back to positive ground by the afternoon. Unable to gather any upside momentum, the rally stalled and the averages limped into the close. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism rose 1.7 points to 96.9 in April, versus expectations for a 96.0 reading. The JOLTs report showed job openings fell 150K to 4.99M in March, versus expectations for 5.11M openings. The 10-year U.S. Treasury yield climbed at high as 2.37% earlier in the session, which was its highest intraday mark since last November, before easing back by midday. Outside of the U.S., bond yields surged on 10-year notes in Japan, Italy, Spain, Portugal, and Germany. COMPANY NEWS: Shares of AOL (AOL) advanced $7.93, or 18.62%, to $50.52 after Verizon (VZ) agreed to buy the company for $50 per share in a deal valued at $4.4B. Verizon's John Stratton, speaking at the Jefferies 2015 Global TMT Conference, said the AOL deal was primarily about ad technology and Re/code reported that "one scenario" the service has heard about is that Verizon plans to spin off some or all of the content operations it is acquiring by buying AOL, such as the Huffington Post. Yahoo (YHOO) also rose 24c, or 0.55%, to $43.84, as Cantor Fitzgerald analyst Youssef Squali said he now views it as the "last remaining large scale digital media company of its kind." MAJOR MOVERS: Among the notable gainers was Pall Corp. (PLL), which advanced $19.31, or 19.44%, to $118.62 after The Wall Street Journal reported that the company is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers. Also higher was Pain Therapeutics (PTIE), which gained 68c, or 35.05%, to $2.62 after announcing that a study of its lead drug candidate, that is specifically designed to discourage certain common methods of drug tampering and misuse, demonstrated with statistical significance that both intact and chewed Remoxy were less "liked" than immediate-release oxycodone on the two primary endpoints of Drug Liking and Drug High. Among the noteworthy losers was ITT Educational Services (ESI), which plunged $1.75, or 43.53%, to $2.27 after the SEC announced that it had charged the company, along with its CEO and CFO, with fraud. Also lower were shares of NewLink Genetics (NLNK), which dropped $15.59, or 29.9%, to $36.55 after stating that it would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to change the statistical analysis plan as defined in the original protocol. INDEXES: The Dow fell 36.94, or 0.2%, to 18,068.23, the Nasdaq slid 17.38, or 0.35%, to 4,976.19, and the S&P 500 dropped 6.21, or 0.29%, to 2,099.12.
16:20 EDTMCKMcKesson authorizes $500M repurchase program
Subscribe for More Information
16:18 EDTMCKMcKesson sees FY16 EPS $12.20-$12.70, consensus $12.57
Sees FY16 distribution solutions revenue growth in mid-single digits. Sees North America pharmaceutical distribution and services delivering high-single digit revenue growth. Sees international pharmaceutical and distribution services revenues flat year-over-year on constant currency basis. Sees medical-surgical distribution and services delivering mid-single digit revenue growth. Sees branded drug price trends in U.S. similar to FY15. Sees price trends on generic drugs outside an exclusivity period, in the U.S. market, slightly below FY15. Sees profit contribution from launch of new oral generic pharmaceuticals in the U.S. market decreasing. Sees technology solutions revenue declining mid-single digits driven by revenue decline in our hospital software business and pending sale of a business line. Guidance assumes adjusted tax rate 31.5%. Sees cash flow from operations $3B.
16:14 EDTMCKMcKesson reports Q4 adjusted adjusted EPS $2.94, consensus $2.75
Subscribe for More Information
15:00 EDTMCKNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include McKesson (MCK), consensus $2.75... Zillow (Z), consensus (12c)... GoDaddy (GDDY), consensus 35c... RSP Permian (RSPP), consensus 17c... Parsley Energy (PE), consensus 0c... Vivint Solar (VSLR), consensus (38c)... New Relic (NEWR), consensus (25c)... Hortonworks (HDP), consensus (86c)... SunOpta (STKL), consensus 7c... OPOWER (OPWR), consensus (16c)... JP Energy Partners (JPEP), consensus (4c)... TubeMogul (TUBE), consensus (18c)... Ducommun (DCO), consensus 30c.
12:42 EDTESIOptions with increasing put volume and implied volatility
Options with increasing put volume and implied volatility: ESI VIPS WETF
12:42 EDTESIITT Educational disagrees with SEC position
Subscribe for More Information
12:37 EDTESIFor-profit education stocks slide after SEC charges ITT with fraud
Subscribe for More Information
11:32 EDTESIITT Educational down 45% after SEC announces fraud charges against company
10:23 EDTESISEC announces fraud charges against ITT Educational Services
Subscribe for More Information
10:01 EDTWDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:56 EDTMCKMcKesson has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO John Hammergren on May 13 at 10:30 am.
07:52 EDTSHPGLeerink to hold a tour
Subscribe for More Information
07:51 EDTMPWRDeutsche Bank to hold a conference
Subscribe for More Information
07:05 EDTWDCWestern Digital initiated with a Buy at Benchmark Co.
Target $117.
06:14 EDTCLColgate-Palmolive to sell laundry brands in Australia & New Zealand to Henkel
Henkel AG & Co. KGaA has signed an agreement with Colgate-Palmolive Company to acquire its entire range of laundry detergents and pre-wash brands in Australia and New Zealand. In total, the brands to be acquired generated sales of about EUR110M in FY14. The purchase price amounts to EUR220M and will be financed in cash. The transaction will be accretive to earnings upon closing. The closing of the transaction is still subject to regulatory approvals and expected to take place in 3Q15.
05:26 EDTDDDuPont issues statement regarding Trian's statements
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use